Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Compare

1,369 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRDN Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Viridian

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRDN Stock 12 Month Forecast

Average Price Target

$38.73

▲(102.35% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $38.73 with a high forecast of $50.00 and a low forecast of $26.00. The average price target represents a 102.35% change from the last price of $19.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","21":"$21","31":"$31","41":"$41","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21,31,41,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.41,19.916923076923077,22.423846153846156,24.930769230769233,27.43769230769231,29.944615384615386,32.45153846153846,34.95846153846154,37.46538461538462,39.972307692307695,42.47923076923077,44.986153846153854,47.49307692307693,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.41,19.05,20.689999999999998,22.33,23.97,25.61,27.25,28.889999999999997,30.529999999999998,32.17,33.81,35.449999999999996,37.089999999999996,{"y":38.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.41,18.07076923076923,18.731538461538463,19.392307692307693,20.053076923076922,20.713846153846156,21.374615384615385,22.035384615384615,22.696153846153848,23.356923076923078,24.017692307692307,24.67846153846154,25.33923076923077,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$38.73

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kelly Shi

Jefferies

$44

Buy

129.89%

Upside

Initiated

08/24/25

Viridian Therapeutics (VRDN) Receives a Buy from JefferiesJefferies analyst Kelly Shi assumes coverage on Viridian Therapeutic (NASDAQ: VRDN) with a Buy rating and a price target of $44.00.

Gavin Clark-Gartner

Evercore ISI

$38

Buy

98.54%

Upside

Reiterated

08/11/25

Evercore ISI Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

Douglas Tsao

H.C. Wainwright

$34

Buy

77.64%

Upside

Reiterated

08/07/25

Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment

Leland Gershell

Oppenheimer

$28→$32

Buy

67.19%

Upside

Reiterated

08/07/25

Viridian Therapeutics (VRDN) Gets a Buy from Oppenheimer

Lisa Walter

RBC Capital

$45→$41

Buy

114.21%

Upside

Reiterated

08/07/25

RBC Capital Remains a Buy on Viridian Therapeutics (VRDN)

Thomas Smith

Leerink Partners

$50

Buy

161.23%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating

Rami Katkhuda

LifeSci Capital

$46

Buy

140.33%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating

Derek Archila

Wells Fargo

$26

Hold

35.84%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments

Laura Chico

Wedbush

$41→$40

Buy

108.99%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments

Serge Belanger

Needham

$36→$34

Buy

77.64%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Ocular Therapeutix (NASDAQ: OCUL)

Alex Thompson CFA

Stifel Nicolaus

$41

Buy

114.21%

Upside

Reiterated

08/04/25

Kalpit Patel

B.Riley Financial

$19

Hold

-0.73%

Downside

Reiterated

05/21/25

B.Riley reiterates Neutral Rating on Viridian Therapeutic (VRDN)B.Riley analyst Kalpit Patel reiterated a Neutral rating and $19.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

Julian Harrison

BTIG

$61

Buy

218.70%

Upside

Reiterated

05/20/25

Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating

Jason Butler

Citizens JMP

$42→$38

Buy

98.54%

Upside

Reiterated

05/07/25

Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMPViridian Therapeutics price target lowered to $38 from $42 at Citizens JMP

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kelly Shi

Jefferies

$44

Buy

129.89%

Upside

Initiated

08/24/25

Viridian Therapeutics (VRDN) Receives a Buy from JefferiesJefferies analyst Kelly Shi assumes coverage on Viridian Therapeutic (NASDAQ: VRDN) with a Buy rating and a price target of $44.00.

Gavin Clark-Gartner

Evercore ISI

$38

Buy

98.54%

Upside

Reiterated

08/11/25

Evercore ISI Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

Douglas Tsao

H.C. Wainwright

$34

Buy

77.64%

Upside

Reiterated

08/07/25

Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment

Leland Gershell

Oppenheimer

$28→$32

Buy

67.19%

Upside

Reiterated

08/07/25

Viridian Therapeutics (VRDN) Gets a Buy from Oppenheimer

Lisa Walter

RBC Capital

$45→$41

Buy

114.21%

Upside

Reiterated

08/07/25

RBC Capital Remains a Buy on Viridian Therapeutics (VRDN)

Thomas Smith

Leerink Partners

$50

Buy

161.23%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating

Rami Katkhuda

LifeSci Capital

$46

Buy

140.33%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating

Derek Archila

Wells Fargo

$26

Hold

35.84%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments

Laura Chico

Wedbush

$41→$40

Buy

108.99%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments

Serge Belanger

Needham

$36→$34

Buy

77.64%

Upside

Reiterated

08/06/25

Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Ocular Therapeutix (NASDAQ: OCUL)

Alex Thompson CFA

Stifel Nicolaus

$41

Buy

114.21%

Upside

Reiterated

08/04/25

Kalpit Patel

B.Riley Financial

$19

Hold

-0.73%

Downside

Reiterated

05/21/25

B.Riley reiterates Neutral Rating on Viridian Therapeutic (VRDN)B.Riley analyst Kalpit Patel reiterated a Neutral rating and $19.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

Julian Harrison

BTIG

$61

Buy

218.70%

Upside

Reiterated

05/20/25

Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating

Jason Butler

Citizens JMP

$42→$38

Buy

98.54%

Upside

Reiterated

05/07/25

Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMPViridian Therapeutics price target lowered to $38 from $42 at Citizens JMP

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viridian Therapeutics

1 Month

xxx

Success Rate

14/29 ratings generated profit

Average Return

+3.87%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 48.28% of your transactions generating a profit, with an average return of +3.87% per trade.

3 Months

xxx

Success Rate

12/23 ratings generated profit

Average Return

+2.06%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +2.06% per trade.

1 Year

Laura ChicoWedbush

Success Rate

20/41 ratings generated profit

Average Return

+1.21%

reiterated a buy rating 30 days ago

Copying Laura Chico's trades and holding each position for 1 Year would result in 48.78% of your transactions generating a profit, with an average return of +1.21% per trade.

2 Years

xxx

Success Rate

14/25 ratings generated profit

Average Return

+21.46%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 56.00% of your transactions generating a profit, with an average return of +21.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRDN Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRDN has received 15 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. VRDN average Analyst price target in the past 3 months is 38.73.

Each month's total comprises the sum of three months' worth of ratings.

VRDN Financial Forecast

VRDN Earnings Forecast

Next quarter’s earnings estimate for VRDN is -$0.95 with a range of -$1.30 to -$0.16. The previous quarter’s EPS was -$1.00. VRDN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 47.42% of the time in the same period. In the last calendar year VRDN has Outperformed its overall industry.

VRDN Sales Forecast

Next quarter’s sales forecast for VRDN is $37.00K with a range of $0.00 to $100.00K. The previous quarter’s sales results were $75.00K. VRDN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.11% of the time in the same period. In the last calendar year VRDN has Outperformed its overall industry.

VRDN Stock Forecast FAQ

What is VRDN’s average 12-month price target, according to analysts?

Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 38.73.

What is VRDN’s upside potential, based on the analysts’ average price target?

Viridian Therapeutics has 102.35% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRDN a Buy, Sell or Hold?

Viridian Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Viridian Therapeutics’s price target?

The average price target for Viridian Therapeutics is 38.73. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $26.00. The average price target represents 102.35% Increase from the current price of $19.14.

What do analysts say about Viridian Therapeutics?

Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of VRDN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

VRDN Analyst Ratings

VRDN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viridian Therapeutics

VRDN Analyst Recommendation Trends

VRDN Financial Forecast

VRDN Earnings Forecast

VRDN Sales Forecast

VRDN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts